diabet retinopathi indic move
fda approv eylea diabet retinopathi upsid limit opinion
expect fda approv eylea treatment form diabet retinopathi
expect much usag eylea alreadi approv treatment
diabet macular edema dme complic diabet retinopathi
caus vision loss requir treatment non-prolif diabet retinopathi
npdr hand gener less symptomat patient simpli
observ current estim us sale eylea diabet
retinopathi indic
non-prolif diabet retinopathi patient gener observ treat
symptom npdr rel benign present see spot
floater blur vision dark center vision difficulti see night
dismiss symptom npdr w/o dme rel underdiagnos
patient diagnos typic observ follow progress
sinc potenti deterior treatment warrant
physician could use laser surgeri attempt stop leaki vessel within eye
base diseas present treatment paradigm think may difficult
convinc patient use inject eye treat diseas non prolif
diabet retinopathi often asymptomat may may worsen near-term
patient may opt observ laser surgeri upon diseas progress
requir repeat inject
base expect spend like exceed compani guidanc
year maintain hold rate pt note higher
spend use rel inflex matter earli pipelin develop
libtayo develop cost higher clinic manufactur cost higher
headcount cost continu expect strong growth dupix moder
growth eylea signific increas spend may continu surpris
price close busi may
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
dupix chronic rhinosinus nasal non-gaap epsp multipl figur revenu build
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapww us ex-u kevzarau ex-u dupixentu atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sell gener collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli epsbas share dilut share outstand figur balanc sheet
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens capit leas oblig defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil convert senior notes- defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
